Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

BDSX - Biodesix, Inc. Последние новости | Finranks

Home

/

BDSX

B

Biodesix, Inc. (BDSX)

NGM – Цена в реальном времени. Валюта: USD

24.00

-0.31 (-1.28%)

Рынок открыт: Aug 12, 2026, 1:01 PM EDT

24.33

+0.02 (0.08%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?

Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?

Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet

Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet

The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix Q2 Earnings Call Highlights

Biodesix Q2 Earnings Call Highlights

Biodesix NASDAQ: BDSX reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its commercial organization.

Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates

Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $1.6 per share a year ago.

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity's 46th Annual Growth Conference, which will be held from August 11-12, 2026.

Видео

No Data

There is no data to display

Пресс-релизы

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity's 46th Annual Growth Conference, which will be held from August 11-12, 2026.